Furthermore, CD6 activation of T cells promotes TCR diversity 59, while CR2-mediated complement pathway activation enhances B cell-driven activation of tumor-specific CD8+ T cells in anti-tumor immunity 60. This evidence concerns the gene CD8A and neoplasm.